The Burden of Iron Deficiency in Heart Failure

Heart failure with reduced ejection fraction represents a major global health challenge that severely impairs quality of life and patient survival. Patients suffering from chronic systolic heart failure frequently exhibit coexisting iron deficiency, regardless of whether anemia is clinically present. Integrating iron therapy in heart failure care has therefore emerged as an essential therapeutic strategy to enhance functional capacity. Systemic inflammation inherent to chronic heart failure significantly impairs intestinal iron absorption and restricts iron release from tissue stores. Consequently, functional iron deficiency develops even when total body iron appears adequate on routine lab panels. Furthermore, iron is essential for mitochondrial respiration and cellular bioenergetics within cardiac and skeletal myocytes. Depletion of cellular iron stores directly causes reduced exercise tolerance, profound fatigue, and heightened hospitalization risks. Clinical studies show that iron deficiency affects over half of all chronic heart failure patients. Therefore, proactive screening and targeted treatment are critical for optimizing patient outcomes and quality of life.

Pathophysiological Mechanisms of Cellular Iron Depletion

The biological mechanisms driving iron depletion in heart failure involve systemic and cellular alterations. Chronic low-grade inflammation increases hepatic synthesis of hepcidin, the key hormone regulating systemic iron balance. Elevated circulating hepcidin levels bind ferroportin channels on enterocytes and macrophages, triggering their degradation. Consequently, dietary iron absorption in the duodenum decreases, while stored iron remains trapped inside reticuloendothelial cells. In addition, passive bowel congestion from elevated venous pressures causes mucosal edema, further compromising nutrient uptake. Concomitant medications like antiplatelets can also cause minor chronic gastrointestinal blood loss over time. At the myocyte level, iron is indispensable for electron transport chain function within mitochondria. When intracellular iron falls, adenosine triphosphate generation drops, severely impairing myocardial contractility and skeletal muscle performance. Thus, iron deficiency represents a fundamental cellular bioenergetic failure rather than a simple hematologic defect. Because enteral absorption pathways are compromised, targeted parenteral repletion is required to bypass intestinal barriers and restore cellular reserves effectively.

Efficacy of Intravenous Iron Therapy in Heart Failure

Selecting the optimal administration route is critical when treating iron deficiency in heart failure. Although oral iron salts are inexpensive and accessible, clinical trials demonstrate that oral formulations fail to restore iron stores in heart failure patients. For example, the IRONOUT-HF trial evaluated high-dose oral iron in patients with reduced ejection fraction and showed no meaningful improvement in exercise capacity or iron stores. This failure stems from elevated hepcidin levels and mucosal edema, which severely impair oral iron absorption. In contrast, intravenous iron therapy in heart failure bypasses gastrointestinal absorption completely, delivering elemental iron directly into systemic circulation. Modern parenteral preparations, such as ferric carboxymaltose and ferric derisomaltose, enable rapid administration of high doses in single sessions. Clinical studies consistently show that intravenous repletion improves symptoms, functional class, and six-minute walk distance. Moreover, intravenous iron exhibits a favorable safety profile with very low rates of severe hypersensitivity. Consequently, guidelines strongly favor intravenous over oral iron supplementation.

Major Clinical Trials and Evidence Synthesis

Substantial randomized controlled trial evidence supports intravenous iron supplementation in heart failure. Early pivotal trials, including FAIR-HF, CONFIRM-HF, and EFFECT-HF, evaluated ferric carboxymaltose in ambulatory patients with reduced ejection fraction. These studies demonstrated significant gains in New York Heart Association functional class, six-minute walk distance, and overall quality of life. Subsequently, the AFFIRM-AHF trial investigated ferric carboxymaltose in patients stabilized after acute heart failure hospitalizations, demonstrating a significant reduction in recurrent heart failure admissions. Similarly, the IRONMAN trial evaluated ferric derisomaltose, confirming sustained clinical benefits and reduced cardiovascular events. Importantly, these benefits occur independently of baseline hemoglobin levels, demonstrating that iron repletion provides advantages beyond correcting anemia. Furthermore, recent meta-analyses confirm that parenteral iron repletion significantly decreases heart failure hospitalizations while maintaining an excellent overall safety profile. Consequently, major international guidelines now establish intravenous iron repletion as a core therapeutic pillar for symptomatic patients with reduced ejection fraction.

Diagnostic Criteria and Clinical Practice Recommendations

Accurate identification of iron deficiency in heart failure requires specific diagnostic thresholds. Guidelines define iron deficiency as serum ferritin under 100 ng/mL, indicating absolute deficiency. Alternatively, functional iron deficiency is diagnosed when ferritin is between 100 and 299 ng/mL with transferrin saturation under 20%. Because ferritin is an acute-phase reactant influenced by inflammation, transferrin saturation is essential for accurate assessment. Clinical guidelines from the European Society of Cardiology and American College of Cardiology recommend routine iron screening for all heart failure patients. Intravenous ferric carboxymaltose or ferric derisomaltose is strongly recommended for symptomatic patients meeting these diagnostic criteria. Implementing inpatient discharge protocols ensures that eligible patients receive iron infusions before leaving the hospital. Additionally, post-treatment reassessment should occur approximately three months post-infusion to confirm repletion and direct further management. Adhering to these standardized protocols optimizes long-term clinical outcomes and reduces heart failure hospitalizations.

How is iron deficiency defined in patients with heart failure?

Iron deficiency in heart failure is defined as serum ferritin below 100 ng/mL, indicating absolute deficiency. Alternatively, functional iron deficiency occurs when serum ferritin is between 100 and 299 ng/mL with a transferrin saturation under 20%. These specific criteria account for the chronic inflammatory state of heart failure, where serum ferritin can be falsely elevated. Screening all heart failure patients with complete iron panels is therefore essential for accurate clinical diagnosis.

Why is oral iron therapy ineffective for heart failure patients?

Oral iron therapy is generally ineffective in heart failure due to impaired gastrointestinal absorption. Chronic heart failure induces low-grade systemic inflammation, elevating circulating hepcidin levels that block intestinal iron transport. Additionally, bowel wall edema caused by venous congestion further impairs nutrient absorption. Clinical trials demonstrate that oral iron fails to significantly increase iron stores or improve exercise capacity, making intravenous iron the preferred therapeutic route for meaningful clinical benefit.

What are the primary clinical benefits of intravenous iron therapy?

Intravenous iron therapy rapidly replenishes body iron stores and improves cellular energy production within cardiac and skeletal muscle. Clinical trials show that intravenous repletion significantly enhances exercise tolerance, alleviates fatigue, and improves New York Heart Association functional class and overall quality of life. Furthermore, intravenous iron therapy reduces recurrent hospitalizations for worsening heart failure in symptomatic patients with reduced ejection fraction, regardless of whether anemia is present at baseline.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should rely on their clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Jadoon Y et al. Is Iron Therapy Indicated for Heart Failure with Reduced Ejection Fraction Patients? Can J Physiol Pharmacol. 2026 Aug 05. doi: 10.1139/cjpp-2026-0014. PMID: 42555980.


2. Cheema B, Chokshi A, Orimoloye O, Ardehali H. Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(25):2674-2689.


3. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.